Research programme: metabolic disease therapeutics - Magnus

Drug Profile

Research programme: metabolic disease therapeutics - Magnus

Alternative Names: Obesity therapeutics - Magnus; Type 2 diabetes mellitus therapeutics - Magnus Metabolic

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Magnus Life Science; University College London
  • Developer Magnus Life Science
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Metabolic disorders; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 21 Jan 2015 Early research in Metabolic disorders in United Kingdom (unspecified route)
  • 21 Jan 2015 Early research in Obesity in United Kingdom (unspecified route)
  • 21 Jan 2015 Early research in Type-2 diabetes mellitus in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top